Group 1 - The company has proposed to purchase liability insurance for its directors, supervisors, and senior management to mitigate operational risks and protect their rights [57][58] - The insurance coverage limit is set at no more than 30 million RMB, with an annual premium not exceeding 250,000 RMB [58] - The proposal requires approval from the shareholders' meeting as the directors and supervisors are the insured parties and will abstain from voting [57][58] Group 2 - The company reported a net loss of 307.93 million RMB for the fiscal year 2024, with an unallocated profit of -272.11 million RMB as of December 31, 2024, exceeding one-third of the paid-in capital of 242.37 million RMB [60][61] - The loss is attributed to a significant decline in the market prices of lithium compounds and derivatives, impacting revenue and gross profit [61] - The company has conducted impairment tests on various assets, leading to substantial impairment provisions, which have further affected the financial results [62] Group 3 - The company plans to cancel 1.17 million stock options that have expired and remain unexercised, which accounts for 0.48% of the total share capital [41][49] - This cancellation is in compliance with the relevant regulations and will not have a significant impact on the company's financial status or operational performance [49][50] - The decision has been approved by the board and the supervisory committee, ensuring that it does not harm the interests of shareholders [50] Group 4 - The company has announced a daily related transaction with its affiliate, Jing Shan Hua Xia Industrial Technology Co., Ltd., with an estimated total amount not exceeding 3 million RMB for leasing factory premises in 2025 [30][31] - This transaction has been approved by the board and does not require further shareholder approval as it does not constitute a major asset restructuring [30][31] - The pricing for the transaction is based on market rates, ensuring fairness and compliance with regulations [35][37] Group 5 - The company has undergone a change in accounting policies in accordance with the Ministry of Finance's new interpretations, which will not have a significant impact on its financial statements [51][55] - The changes are aimed at ensuring that the company's financial reporting remains accurate and compliant with the latest regulations [55]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000925 证券简称：众合科技 公告编号：定2025-003 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 √适用 □不适用 代扣代缴个税手续费 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经 ...

Core Viewpoint - The company has announced the provision for asset impairment, reflecting a cautious approach in accordance with accounting standards and regulations [8][11][24]. Financial Data - The first quarter report for 2025 has not been audited [3][7]. - The company has reported a total provision for bad debts of 6,890,455.28 yuan, with a reversal of 2,020,373.58 yuan [9]. - The provision for inventory impairment amounts to 133,476.69 yuan, with a write-off of 2,048.70 yuan [10]. Shareholder Information - The company has confirmed that there are no changes in the top ten shareholders due to the lending or returning of shares [5]. Board and Supervisory Committee Decisions - The board and supervisory committee have both approved the asset impairment provision, confirming its compliance with accounting standards and reflecting the company's financial status accurately [12][24]. - The board meeting held on April 29, 2025, had full attendance and passed the resolution with unanimous support [16][20].

Core Viewpoint - The company has disclosed its financial performance and significant events, including the issuance of new shares and the provision for asset impairment, reflecting its ongoing financial management and strategic adjustments in response to market conditions [3][6][15]. Financial Data Summary - The company reported a total asset impairment provision of 27,617,741.97 yuan for the first quarter of 2025, which will reduce the net profit attributable to the parent company by 27,588,451.58 yuan after considering tax effects [15][17]. - The company has not restated or adjusted previous years' financial data, indicating stability in its accounting practices [3][4]. Share Issuance and Capital Management - The company received approval from the China Securities Regulatory Commission to issue up to 27,792 million new shares, with the issuance completed on August 4, 2023, increasing the total shares from 926,400,000 to 1,136,373,753 [6][7]. - The company plans to continue using idle raised funds for cash management, with a limit of 400 million yuan for a period not exceeding 12 months [10]. Asset Impairment and Financial Health - The company conducted a comprehensive review of its assets, including inventory and receivables, leading to the decision to provision for asset impairment based on prudence and market conditions [16][18]. - The audit committee has confirmed that the asset impairment provision is in accordance with accounting standards and reflects the company's financial condition accurately [18]. Corporate Governance and Accountability - The board of directors and senior management have guaranteed the accuracy and completeness of the quarterly report, accepting legal responsibility for any misstatements [2][3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688310 证券简称：迈得医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688193 证券简称：仁度生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688399 证券简称：硕世生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 2025年第一季度，外部环境压力仍然存在，公司通过海外市场提速、内部精细化管理举措的不断落地， 积极应对市场挑战，业务继续向正常发展轨道回归。报告期内公司实现营业收入0.92亿元，同比增长 0.54%，环比增长12.37%，呈现稳步恢复态势。 单位：元 币种：人民币 收入端：报告期内，公司海外市场保持良好增长势头。得益于先前的产品认证和海外市场的战略部署， 公司海外收入同比增长69.00%。 利润端：随着体外诊断行业集采在全国 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a significant increase in investment income, with both year-on-year and quarter-on-quarter growth exceeding 100%. The quarterly stock quality impairment provision was reversed, contributing positively to profits [1][6] - For Q1 2025, the company achieved revenue of 5.38 billion yuan, a year-on-year increase of 49.1% and a quarter-on-quarter increase of 5.3%. The net profit attributable to the parent company was 1.44 billion yuan, representing a year-on-year increase of 62.0% and a quarter-on-quarter increase of 28.8 times [4][6] - The company’s weighted ROE for Q1 2025 was 1.79%, an increase of 0.68 percentage points year-on-year [4] Financial Data and Profit Forecast - The company’s revenue for 2025 is projected to be 24.69 billion yuan, with a year-on-year growth rate of 28.7% [5] - The net profit attributable to the parent company for 2025 is estimated at 5.81 billion yuan, reflecting a year-on-year growth of 73.3% [5] - The annualized investment return rate for Q1 2025 reached 8.99%, compared to 5.32% in 2024 and 3.34% in Q1 2024 [6] Business Performance - The company’s management expenses for Q1 2025 were 2.21 billion yuan, showing a year-on-year increase of 38% but a quarter-on-quarter decrease of 18%, leading to a net profit margin of 27%, up 2 percentage points year-on-year [6] - The company’s brokerage and margin financing performance was below industry standards, with a decline in customer assets by 11% compared to the end of 2024 [6] - The company’s financial investment scale at the end of Q1 2025 was 226 billion yuan, a 1% increase from the end of the previous year [6]

2024年，公司及子公司在不影响公司正常经营资金需求和确保资金安全的前提下，使用部分暂时闲置的 自有资金进行委托理财，总额度不超过10亿元。截至2024年12月31日，未到期理财余额为5.13亿元。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司关于 2024年度证券投资情况的专项说明》。 （十）《智度科技股份有限公司2025年度董事薪酬方案》 因该事项与全体董事存在利害关系，因此全体董事回避表决，本议案将直接提交公司股东会审议。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司2025年 度董事、监事及高级管理人员薪酬方案》。 登录新浪财经APP 搜索【信披】查看更多考评等级 （九）《智度科技股份有限公司关于2024年度证券投资情况的专项说明》 表决结果：五票同意、零票反对、零票弃权。本议案获得通过。 表决结果：三票同意、零票反对、零票弃权。本议案获得通过。 关联董事陆宏达先生和刘广飞先生回避表决。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司关于 ...

股票代码：600590 股票简称：泰豪科技 公告编号：临2025-035 泰豪科技股份有限公司关于子公司引入 战略投资者对其增资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、交易概述 泰豪科技股份有限公司（以下简称"公司"）分别于2022年9月、2023年6月先后召开第八届董事会第九次 会议、2022年第二次临时股东大会、第八届董事会第十五次会议,并审议通过了《关于全资子公司拟引 入战略投资者及员工持股平台对其增资的议案》和《关于子公司拟引入战略投资者对其增资的议案》， 同意子公司江西泰豪军工集团有限公司（以下简称"泰豪军工"）引进战略投资者北京国发航空发动机产 业投资基金中心（有限合伙）（以下简称"航发基金"）、榆林市煤炭资源转化引导基金合伙企业（有限 合伙）（以下简称"榆煤基金"）、重庆泰和峰私募股权投资基金合伙企业（有限合伙）（以下简称"重 庆泰和峰"）、中兵国调（厦门）股权投资基金合伙企业（有限合伙）（以下简称"中兵国调基金"）、 中兵投资管理有限责任公司（以下简称"中兵投资"）以及员工持股平台共青城 ...